Business
WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform
WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform. Earendil Labs is an AI-powered biotech company focused on researching and developing next-generation innovative biologics for the treatment of autoi
About this update from Wuxi Xdc Cayman, Inc.
[{"type":"text","content":"SHANGHAI, Feb. 27, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform. Earendil Labs is an AI-powered biotech company focused on researching and developing next-generation innovative biologics for the treatment of autoimmune diseases, cancer, and other conditions with unmet medical needs. This collaboration marks the establishment of a robust strategic partnership aimed at accelerating the development of next-generation ADCs by synergistically combining WuXi XDC's globally leading ADC technology platform with Earendil Labs' cutting-edge AI-driven antibody discovery and development capabilities to address significant unmet medical needs.","length":992,"tagName":"p"},{"type":"image","alt":"Jimmy Li, PhD, CEO of WuXi XDC (left); Jian Peng, PhD, CEO of Earendil Labs (right)","displaySize":"","headline":null,"caption":"Jimmy Li, PhD, CEO of WuXi XDC (left); Jian Peng, PhD, CEO of Earendil Labs (right)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/1061ab8385ddf4bf5e9cf799f1dcae8d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VheKdDr9rsYD5lbAyfeLqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1061ab8385ddf4bf5e9cf799f1dcae8d","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2922035/image_5027433_28984379.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the agreement, WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary WuXiTecan-2 payload-linker technology for use against multiple specific targets. Earendil Labs will utilize this technology to conjugate antibodies and bispecific antibodies discovered through its AI platform and to advance the development of the ADC candidates against these specific targets. The total potential deal value could reach up to approximately $885 million, comprising an upfront payment, and certain development, regulatory, and sales milestone payment...